NCT06661148尚未招募1 期
A Phase 1, Open-Label, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients.
Epigenic Therapeutics, Inc1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
研究概览
简要总结
This study is an open-label, 2-Part (Single Ascending Dose [Part 1] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself. This study is designed to determine the safety and pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPI-003 in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 65 years (inclusive) at the time of signing the informed consent.
- •Body mass index (BMI) ≥ 18 kg/m2 and ≤ 35 kg/m2 at Screening, and body weight of ≤ 120 kg.
- •Chronic HBV infection for ≥ 6 months prior to Screening (eg, positive for serum HBsAg, HBV DNA, HBeAg for ≥ 6 months ) or serum immunoglobulin M (IgM) anti-HBc (hepatitis B core antibody) negative at Screening; AND Baseline HBsAg positive at Screening.
- •Has received treatment with a NA (entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide) as a stable dose for ≥ 6 months before Screening and plans to continue at the same dose level for the duration of the study. Participants may be on other NAs but require Sponsor approval before enrolment.
- •HBV DNA < LLOQ (according to local guidelines) for ≥ 6 months and at Screening
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of normal (ULN) at Screening.
- •Able and willing to attend the necessary visits to the study site.
- •Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.
排除标准
- •Evidence or history of liver disease of non-HBV aetiology.
- •Previous history or current diagnosis of significant liver fibrosis or cirrhosis
- •Liver ultrasound or other imaging with findings suggestive of HCC at any time.
- •Participants with serum alpha-fetoprotein (AFP) ≥ 200 ng/mL at Screening.
- •Positive test result for HIV-1 or HIV-2 that suggests a concurrent infection at Screening.
- •History of acute febrile illness, symptomatic viral, bacterial, or fungal infection within 1 week before Day
- •History of receiving HBV vaccine or other HBV-targeted therapeutic within the 6 months before Day
- •Previous treatment with an HBV-targeted treatment other than NAs within the 6 months before Day 1 or planned use during the study.
- •Any of the laboratory values at Screening (Screening laboratory tests may be repeated once for values thought to be erroneous OR not clinically significant as per the PI):
- •Immunodeficient or autoimmune conditions due to disease.
- •Chronic treatment with immunosuppressants.
- •Any history of unexplained blackouts, fainting episodes, significant arrythmias, clinically significant abnormality of ECG, marked QT abnormalities, or any known risk factors for Torsade de Points
- •History of anaphylaxis, hypersensitivity, or significant drug allergies.
- •Received any antiplatelet or antithrombotic therapy.
- •History of thrombophilia or history of a positive genetic test for Factor V Leiden and/or prothrombin
- •Known or suspected intolerance or hypersensitivity to the IP components.
- •Have received any other IP within 30 days or 5 half-lives of Day
- •Have received any vaccination within 14 days prior to Day 1 or vaccination planned for 3 months following administration of IP.
- •Received any medications or other treatments that may adversely affect the immune system.
- •Excess alcohol consumption within 3 months of Screening.
- •Significant drug abuse/addiction within 3 months of Screening.
- •Any safety concern or personal condition that is inappropriate for study participation per the Investigator's judgement.
研究组 & 干预措施
EPI-003 group
Experimental
Part A：Single Ascending Dose； Part B：Dose Expansion
干预措施: EPI-003 (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
时间窗: From Baseline through to Day 28 postdose
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
次要结局
- Change from baseline at different follow-up time points for HBsAg, HBsAb, HBV DNA, HBV pgRNA and HBcrAg(From Baseline (predose on Day 1) at Day 3, Day 7, Day 14, Day 28, Day 56, Day 84, Day 112, and Day 182, and Day 365 postdose for the following parameters)
- Evaluation of maximum observed concentration (Cmax)(Day 1, Day 3, Day 14, and Day 28)
- Evaluation of maximum observed concentration (tmax)(Day 1, Day 3, Day 14, and Day 28)
- Evaluation of terminal elimination half-life (t1/2)(Day 1, Day 3, Day 14, and Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy VolunteersBladder CancerNCT06034015Jiangsu Yahong Meditech Co., Ltd aka Asieris48
Unknown
1 期
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell LymphomaB-cell Non-Hodgkin LymphomaNCT04296461UWELL Biopharma20
已完成
1 期
Phase I Study in Patients With Solid TumoursNeoplasmsNCT00496028AstraZeneca148
已完成
1 期
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other CancersCarcinoma, MidlineNCT01587703GlaxoSmithKline196
进行中（未招募）
1 期
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05518045LaNova Medicines Limited392